Evaluating the Association between Assisted Conception and the Severity of Preeclampsia by Calhoun, Kathryn C. et al.
International Scholarly Research Network
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 928592, 5 pages
doi:10.5402/2011/928592
Clinical Study
Evaluating the Association betweenAssisted Conception and
t heSev e rityo fP r eec la mps ia
Kathryn C. Calhoun,1 KurtT.Barnhart,2 Michal A. Elovitz,2 andSindhuK. Srinivas2
1Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill,
NC 27599-7570, USA
2Department of Obstetrics and Gynecology, The Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia,
PA 19104, USA
Correspondence should be addressed to Kathryn C. Calhoun, kathryn calhoun@med.unc.edu
Received 9 August 2011; Accepted 7 September 2011
Academic Editors: R. Jones and S. San Martin
Copyright © 2011 Kathryn C. Calhoun et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective. To investigate the association between assisted conceptions and preeclampsia (PEC), including assessment of severity of
disease.Methods.Inaprospectivecasecontrolstudy, caseswereselected fromwomen withpreeclampsiaand controlsfromwomen
without preeclampsia. Exposure was deﬁned as assisted conception with intrauterine insemination or in vitro fertilization (IUI or
IVF). We assessed the association between exposure and outcome, using Chi square or Fisher’s exact tests. Stratiﬁed analyses
and multivariable logistic regression were used to control for confounders. Results. Preeclampsia was associated with assisted
conception after controlling for age and race (AOR 2.2, [1.03–4.72]). All women with preeclampsia who had assisted conceptions
demonstrated severe disease and were more likely to have abnormal lab values: AST >45 (AOR=6.01 [1.63–22.21] P = 0.007),
creatinine ≥1 (AOR 2.92 [0.82–10.4], P = 0.09) or platelets <100 (AOR 5.74 [1.00–32.76] P = 0.049), after adjusting for race, age,
and multiple gestations. Conclusion. Assisted conceptions are associated with a more severe preeclamptic phenotype.
1.Introduction
Infertility aﬀects approximately 12% of the reproductive age
population, and in vitro fertilization (IVF) is employed for
approximately 1% of live births in the United States [1].
IVF has been associated with subsequent maternal and fetal
morbidity, including preeclampsia [2].
Preeclampsia aﬀects 5–8% of all pregnancies, contributes
to fetal morbidity, and is recognized as a leading cause of
maternal mortality [3]. While the exact etiology of the dis-
ease remains poorly understood, it is theorized that pree-
clampsia stems from events related to placentation [4–6].
Despite this small window of time for a seemingly uniform
early pregnancy insult, preeclampsia has a large spectrum of
disease presentation, from simple hypertension to end-organ
damage involving multiple organ systems.
Because assisted conceptions involve more exogenous
manipulation of the embryo and/or uterine milieu, we hy-
pothesized that we would ﬁnd a more severe phenotype of
preeclamptic disease in these pregnancies. While previous
studies have reported associations between pregnancy-relat-
ed hypertensive disease and IVF in both singleton pregnan-
cies and multiple gestations, no study has examined the link
between assisted conceptions and disease phenotype, specif-
ically the severity of disease [2, 7–13].
The objectives of this study were to further explore the
association between assisted conceptions and preeclampsia




We performed a planned secondary analysis of patients en-
rolledinacase-controlstudy,Preeclampsia:Mechanismsand
Consequences between March 2005 and August 2007 at the
Hospital of the University of Pennsylvania.2 ISRN Obstetrics and Gynecology
Institutional Review Board approval was obtained prior
to enrollment. Cases were deﬁned as women with gestational
hypertension or preeclampsia. Controls were deﬁned as
women presenting for delivery at term (≥37 weeks) without
gestational hypertension or preeclampsia. All women admit-
ted to Labor and Delivery with preeclampsia were eligible for
enrollment and invited to participate in the overall study.
Cases were identiﬁed based on maternal criteria for pree-
clampsia. Controls were prospectively enrolled from all
women presenting for delivery at term (≥37 weeks) for
scheduled induction of labor, scheduled cesarean section,
spontaneous rupture of membranes, or term labor. There
were no exclusion criteria for either cases or controls in the
overall study. Cases and controls were frequency matched for
race (African American versus other).
Diagnostic criteria for preeclampsia were determined per
ACOG guidelines, and disease classiﬁcation was determined
by the primary investigators (SKS and MAE) and not by
the physician caring for the patient [14]. Mild preeclampsia
included the diagnosis of gestational hypertension and was
deﬁned as elevated blood pressure (140/90mmHg or greater
on two measurements that were obtained six or more hours
apart, or 160/105mmHg or greater at time of admission)
with proteinuria ≤+1 on urine dip. Severe preeclampsia was
deﬁned as blood pressure 160/105mmHg with greater than
+1onurinedipor ≥140/90mmHgontwooccasions6hours
apart and any one of the following: platelets <120,000/mL,
aspartate aminotransferase (AST) >45U/L, alanine amino-
transferase (ALT) >60U/L, and/or creatinine ≥1.0. Severe
disease also included women diagnosed with HELLP (He-
molysis, Elevated Liver Enzymes Low Platelets) syndrome
or eclampsia, women who required intravenous antihyper-
tensive medications prior to delivery (as a surrogate for
blood pressure values persistently in the severe range), or
iatrogenic preterm delivery (<37 weeks) due to the severity
of their disease. Additional descriptions of this study are pro-
vided elsewhere [15, 16].
Trained research nurses collected information on height,
race, ethnicity, conception history (spontaneous or assisted),
and history of chronic hypertension (CHTN) by patient
interview at the time of enrollment. Other history including
obstetric, demographic, prenatal, delivery, and neonatal in-
formation was collected from prenatal and hospital chart
abstraction by trained research nurse abstractors. A separate
individualperformeddataentry.Intrauterinegrowthrestric-
tion was deﬁned using actual birth weight and the Alexander
growth curve to determine percentile fetal growth for
gestational age [17].
In our study, exposure was deﬁned as assisted conception
and further subdivided into intrauterine insemination (IUI)
or in vitro fertilization (IVF). The IUI group included use
of clomiphene citrate and injectable gonadotropins. The IVF
group also included all conceptions with or without intracy-
toplasmic sperm injection (ICSI).
Chi square analysis or Fisher’s exact tests were used to
compare categorical variables, and Student’s t tests were used
for normally distributed continuous variables. Confounding
variables were selected based on biologically plausible asso-
ciations, prior literature reports, or statistical signiﬁcance.
Multivariable logistic regression was used to control for the
following confounders: maternal age, maternal race, and
multiple gestation. A P value of less than 0.05 was considered
statistically signiﬁcant.
We performed an initial analysis to conﬁrm the previ-
ously reported association between the use of assisted con-
ception and preeclampsia [2]. We subsequently performed
analyses restricted to only women with preeclampsia (cases
only). The purpose of these subsequent analyses was to eval-
uatetheassociationbetweenassistedconceptionandseverity
of disease (phenotype) among women with preeclampsia.
The comparison of maternal and pregnancy characteristics
and severity of preeclampsia between assisted and unassisted
pregnancies was performed using Chi square and Fisher’s
exact tests. Multivariable logistic regression was used to con-
trol for confounders. Finally, analyses were also performed
restricted to those who conceived with IVF compared to
those with an unassisted conception.
3. Results
A total of 1031 patients were enrolled in the overall study.
440 women were diagnosed with preeclampsia, and 591
women were controls. Within the cases, 16 women (3.6%)
hadassistedconceptions(4IUI,12IVF),and424womenhad
unassisted pregnancies. Within the control population, 16
women (2.7%) had assisted conceptions (11IUI, 5IVF), and
575 women conceived without assistance.
Table 1 shows a demographic comparison of the cases
v e r s u sc o n t r o l s .C a s e sw e r em o r el i k e l yt ob eA f r i c a nA m e r -
ican and primiparous. Cases were also more likely to be
carrying multiple gestations and to have a history of chron-
ic hypertension (CHTN) and a previous history of pree-
clampsia.
An unadjusted analysis demonstrated that women with
preeclampsia (cases) had a 1.4 times higher odds (CI0.63–
2.93, P = 0.4) of having an assisted conception than women
without preeclampsia. However, after controlling for age
and race, women with preeclampsia had a two-times higher
odds of having an assisted conception than women without
preeclampsia (AOR 2.2, [1.03–4.72], P = 0.042). The as-
sociation was stronger when the adjusted analysis (adjusted
for age, race, and multiple gestation) was restricted to con-
ception after IVF (AOR 5.3, [1.74–15.89], P = 0.003). No
association was noted between conception with IUI and
preeclampsia (AOR 0.83, [0.25–2.72], P = 0.76) (Table 2).
We next performed analyses restricted to only women
withpreeclampsia(casesonly).Table 3 showsademographic
comparison of preeclamptic women that conceived with and
without assistance. Women with preeclampsia with assisted
c o n c e p t i o n sw e r em o r el i k e l yt ob eo l d e ra n dn o n - A f r i c a n
American, and to be carrying multiple gestations than those
womenwithpreeclampsiaandunassistedconceptions.Adis-
easephenotypecomparisonbetweenthetwogroupsrevealed
severe preeclampsia in all cases with assisted conceptions.
This severity manifested as proteinuria and laboratory ﬁnd-
ings consistent with the end-organ damage associated with
HELLP syndrome rather than as signiﬁcant hypertensionISRN Obstetrics and Gynecology 3




(N = 591) P value
Mean age 26.8 +/− 6.9 27.2 +/− 6.6 0.42
Race (African American) 84.8 (373) 74.5 (440) 0.0001
Mean BMI at screening 29.9 +/− 8 28.9 +/− 7.6 0.06
Primiparous 33.4 (147) 22.7 (134) 0.0002
Mean gest age at delivery 36.1 +/− 3.7 39.2 +/− 1.2 <0.001
Twin Pregnancy 5.2 (23) 0 (0) <0.0001
Pregestational diabetes 4.1 (18) 2.2 (13) 0.12
Gestational diabetes 3.9 (17) 2.2 (13) 0.17
Chronic hypertension 15.5 (68) 5.3 (31) 0.0001
History of preeclampsia 20.9 (92) 7.6 (45) 0.0001
History of preterm
preeclampsia 9.8 (43) 2.0 (12) 0.0001
Tobacco use 12.1 (53) 10.3 (61) 0.44
Table 2: Assisted conception: preeclamptic cases versus non-preeclamptic controls†.
Type of treatment Unadjusted OR 95% CI Adjusted OR 95% CI P value
All assisted‡ (IVF + IUI) 1.4 0.63–2.93 2.2 1.03–4.72 0.042
IVF§ 3.3 1.1–11.9 5.3 1.74–15.89 0.003
IUI¶ 0.49 0.11–1.7 0.83 0.25–2.72 0.76
†Adjusted for age and race.
‡Assisted pregnancies included use of clomiphene citrate, gonadotropins, IUI, IVF, ICSI, and donor egg.
§IVF pregnancies employed in vitro fertilization for conception.
¶IUI group included use of clomiphene citrate and gonadotropins. IVF was not used in this group.
(Table 4). After controlling for age, race, and multiple ges-
tations, there was a signiﬁcant association between assisted
conception and laboratory ﬁndings consistent with end-
organ damage: elevated AST (AOR 6.01 [1.63–22.21], P =
0.07), platelets less than 100,000 (AOR 5.74 [1.00–32.76],
P = 0.049), and elevated creatinine (AOR 2.92 [0.82–10.4],
P = 0.09).
A subsequent analysis further restricted to preeclamptic
womenwhoconceivedwithIVF(excludingIUI)alsodemon-
strated evidence of the same end-organ damage: elevated
AST (AOR 4.9 [1.00–24.31], P = 0.05), platelets less than
100,000 (AOR 18.2 [1.6–21.03], P = 0.02), and elevated cre-
atinine (AOR 8.0 [1.45–44.21], P = 0.02), compared to
women with preeclampsia with unassisted conceptions.
4. Discussion
I no u rs t u d y ,w ew e r ea b l et od e m o n s t r a t ean o v e ld i ﬀerence
in the severity of the phenotype of preeclampsia based on
mode of conception. Women with assisted conceptions, par-
ticularly those who had employed IVF, were signiﬁcantly
more likely to manifest a severe disease characterized by
laboratory ﬁndings consistent with end-organ damage. Ab-
normalities in transaminases, platelets, and creatinine sug-
gest liver, endothelial, and renal damage, respectively, which
can have implications for acute and chronic maternal mor-
bidity and neonatal morbidity. Recent population-based
retrospective cohort studies have illustrated this potential for
ongoingmorbidity,suggestingthatpregnancy-relatedhyper-
tensive disorders are associated with maternal risk of early-
onset cardiovascular disease and death from cardiovascular
causes [3, 18].
Infertility aﬀects a growing subset of the U.S. popula-
tion, and accordingly, assisted conceptions will continue to
account for a larger proportion of births. Studies focusing on
maternal and fetal outcomes following assisted conception
have identiﬁed pregnancy-related hypertensive disorders
among the potential associated adverse outcomes. A 2004
meta-analysis by Jackson et al. comparing 12,283 IVF sin-
gleton births to 1.9 million unassisted singleton births de-
tected higher rates of morbidity in the IVF group including
preeclampsia [8]. Shevell et al. compared spontaneous preg-
nancies (n = 36, 062) to pregnancies conceived with ovula-
tion induction (n = 1222) and IVF (n = 554) and found
that IVF was shown to be associated with gestational hy-
pertension (OR 1.6 [1.0–2.5], P = 0.036), preeclampsia (OR
2.7 [1.7–4.4], P<0.001), placental abruption (OR 2.4 [1.1–
5.2], P = 0.03), and placenta previa (OR 6.0 [3.4–10.7], P<
0.001) [2]. The etiology of these associations is unknown,
but, with more women seeking fertility therapies, it is es-
sential that we expand our knowledge, as gestational hyper-
tensive disorders have implications for signiﬁcant acute and
long-term morbidity and mortality.
The strengths of our study are that it includes extensive
measurements of prenatal, intrapartum, and postnatal data.4 ISRN Obstetrics and Gynecology




(N = 424) P value
Mean age 37.3 +/− 5 26.4 +/− 6.7 <0.001
Race (African American) 18.8 (3) 87.3 (370) <0.0001
Mean BMI at screening 27.8 +/− 6.8 30 +/− 80 . 3 1
Primiparous 75 (12) 50.5 (214) 0.095
Gestational age at delivery 33.8 +/− 4.2 36.1 +/− 3.7 0.01
Twin pregnancy 56.3 (9) 3.1 (13) <0.0001
Pregestational diabetes 0 4.3 (18) 0.84
Gestational diabetes 6.3 (1) 3.8 (16) 0.88
Chronic hypertension 6.3 (1) 15.8 (67) 0.49
History of preeclampsia 18.8 (3) 21.0 (89) 0.93
History of preterm preeclampsia 6.3 (1) 11.8 (50) 0.78
Tobacco use 0 12.5 (53) 0.26
†Assisted pregnancies included use of clomiphene citrate, gonadotropins, IUI, IVF, ICSI, and donor egg,
‡Women with unassisted pregnancies did not report use of clomiphene citrate, gonadotropins, IUI, IVF, ICSI, or donor egg for conception.




(N = 424) P value
Severe disease 100 (16) 60.9 (258) 0.0036
Systolic BP >160 56.3 (9) 78.8 (334) 0.068
Diastolic BP >105 37.5 (6) 34.7 (147) 0.97
IV BP medication 25 (4) 25.2 (107) 0.79
Proteinuria ≥2+ 75 (12) 35.4 (150) 0.0031
Creatinine ≥1.0 50 (8) 18.6 (79) 0.0056
AST ≥45 62.5 (10) 20.3 (86) 0.0002
ALT ≥60 31.3 (5) 11.3 (48) 0.0441
Platelets <100 25 (4) 6.4 (27) 0.0182
IUGR <10% 50 (8) 27.4 (116) 0.09
†Assisted pregnancies included use of clomiphene citrate, gonadotropins, IUI, IVF, ICSI, and donor egg,
‡Women with unassisted pregnancies did not report use of clomiphene citrate, gonadotropins, IUI, IVF, ICSI, or donor egg for conception.
Both the exposure and the outcome were prospectively
collected and speciﬁcally, information regarding the mode of
conception was collected at the time of enrollment by patient
interview.Further,diagnosisandseverityofhypertensivedis-
ease were decided from standardized, objective, prespeciﬁed
criteria rather than by physician report. Additionally, the ex-
tent of our disease severity data and the number of women
with preeclampsia in our case control study allowed us to
evaluate severity of preeclampsia associated with assisted
conceptions in our population.
An additional strength was the use of logistic regression
to control for potential confounding factors such as differen-
ces in age, race, and multiple gestations between our groups.
Despite the inherent reduction in power with a multivariable
analysis, we were able to demonstrate for the ﬁrst time
that, among women with preeclampsia, those with assisted
conceptions manifested a more severe disease phenotype.
Therearealsosomelimitationstoourstudy.Thenumber
of pregnancies conceived with medical assistance, though
representative of our population, is small. Further, informa-
tion regarding the details of the assisted conceptions (dose of
medication or culture conditions used in IVF) and the etiol-
ogy of the patients’ infertility were unavailable. Additionally,
while some may have excluded women with chronic hyper-
tension and a history of preeclampsia, we believe that the
inclusion of these patients is important, makes our ﬁndings
more generalizable, and should not impact our within-case
analyses evaluating disease severity. Lastly, in performing a
case control study, the control population is subject to scru-
tiny. We did not match controls by gestational age. How-
ever, the association between IVF and preeclampsia is not
gestational age dependent and has been demonstrated in
previous work [2, 8]. Further, our analyses evaluating the
disease severity was restricted to women with preeclampsia
and does not involve the control population.
Possible mechanisms for the association between assisted
conception and preeclampsia include defects or deﬁcien-
cies in implantation or placentation, and/or problems withISRN Obstetrics and Gynecology 5
the uterine milieu or in vitro culture conditions. Reports
of increased rates of preeclampsia and gestational diabetes,
together with abruption and previa in pregnancies conceived
with IVF, certainly favor a placental origin for these adverse
outcomes. During implantation, fetal trophoblasts invade
the decidua to eventually access the maternal vasculature.
Truncated or ﬂawed vascular invasion may result in placental
insuﬃciency, and an inability to respond to the demands of a
growing pregnancy may trigger third-trimester pathologies
such as preeclampsia [4]. When assisted conceptions were
divided into IVF and IUI, IVF was associated with a signif-
icantly increased risk of preeclampsia whereas IUI was not.
The increased manipulation of embryo and uterine milieu in
IVF cycles may aﬀect implantation and possibly predispose
to more severe third-trimester pathologies. Invasion of ma-
ternal vasculature may be quantitatively or qualitatively dif-
ferent from an in vivo conception, thus predisposing to
preeclampsia by disruption of placental events by the path-
ways theorized above.
5. Conclusion
While the majority of children conceived with medical as-
sistance are born healthy after an uncomplicated pregnancy,
this paper presents novel information regarding the associ-
ation between assisted conception and altered maternal and
perinatal outcomes, in that a more severe phenotype, with
suggestion of end-organ damage, was seen in assisted con-
ceptions.
Future research should examine the impact of fertility
treatmentsonplacentationandthird-trimestermorbidity.In
addition,womenseekingfertilitytreatmentsshouldbecoun-
seled that these risks exist and that increased surveillance in
the third trimester may be warranted.
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